FDA Approves Genentech’s Alecensa For ALK-positive Early-Stage Lung Cancer

(RTTNews) – Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer or

admin